Is ZNTL or INBX more profitable?

Zentalis Pharmaceuticals' return on equity of -53.61% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -53.61% -40.67% Inhibrx Biosciences N/A -563.90% -72.32%

Does the media prefer ZNTL or INBX?

In the previous week, Zentalis Pharmaceuticals had 5 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 7 mentions for Zentalis Pharmaceuticals and 2 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 1.45 beat Zentalis Pharmaceuticals' score of 0.65 indicating that Inhibrx Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibrx Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, ZNTL or NNNN?

Anbio Biotechnology has higher revenue and earnings than Zentalis Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zentalis Pharmaceuticals N/A N/A -$137.06M -$1.73 N/A Anbio Biotechnology $8.65M 164.74 $6.40M N/A N/A

Is ZNTL or NNNN more profitable?

Anbio Biotechnology's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -53.61% -40.67% Anbio Biotechnology N/A N/A N/A

Which has higher valuation & earnings, CRVS or ZNTL?

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corvus Pharmaceuticals N/A N/A -$15.28M -$0.52 N/A Zentalis Pharmaceuticals N/A N/A -$137.06M -$1.73 N/A

Is CRVS or ZNTL more profitable?

Corvus Pharmaceuticals' return on equity of -38.92% beat Zentalis Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Corvus Pharmaceuticals N/A -38.92% -35.75% Zentalis Pharmaceuticals N/A -53.61% -40.67%

Does the media favor CRVS or ZNTL?

In the previous week, Zentalis Pharmaceuticals had 4 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 7 mentions for Zentalis Pharmaceuticals and 3 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.50 beat Zentalis Pharmaceuticals' score of 0.65 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corvus Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zentalis Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ARDX or ZNTL?

In the previous week, Ardelyx and Ardelyx both had 7 articles in the media. Zentalis Pharmaceuticals' average media sentiment score of 0.65 beat Ardelyx's score of 0.08 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Zentalis Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PAHC or ZNTL?

In the previous week, Zentalis Pharmaceuticals had 3 more articles in the media than Phibro Animal Health. MarketBeat recorded 7 mentions for Zentalis Pharmaceuticals and 4 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.59 beat Zentalis Pharmaceuticals' score of 0.65 indicating that Phibro Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Zentalis Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zentalis Pharmaceuticals (ZNTL) Competitors

$4.33 -0.12 (-2.70%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$4.28 -0.05 (-1.25%)

As of 07/24/2026 07:34 PM Eastern

Compare

ZNTL vs. INBX, NNNN, CRVS, ARDX, and PAHC

Should you buy Zentalis Pharmaceuticals stock or one of its competitors? MarketBeat compares Zentalis Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zentalis Pharmaceuticals include Inhibrx Biosciences (INBX), Anbio Biotechnology (NNNN), Corvus Pharmaceuticals (CRVS), Ardelyx (ARDX), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry.

How does Zentalis Pharmaceuticals compare to Inhibrx Biosciences?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Zentalis Pharmaceuticals' return on equity of -53.61% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%
Inhibrx Biosciences	N/A	-563.90%	-72.32%

82.5% of Inhibrx Biosciences shares are owned by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are owned by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Zentalis Pharmaceuticals has higher earnings, but lower revenue than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	N/A	N/A	-$137.06M	-$1.73	N/A
Inhibrx Biosciences	$1.30M	920.32	-$140.05M	-$8.39	N/A

In the previous week, Zentalis Pharmaceuticals had 5 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 7 mentions for Zentalis Pharmaceuticals and 2 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 1.45 beat Zentalis Pharmaceuticals' score of 0.65 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibrx Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zentalis Pharmaceuticals presently has a consensus target price of $6.75, indicating a potential upside of 55.89%. Inhibrx Biosciences has a consensus target price of $150.00, indicating a potential upside of 83.94%. Given Inhibrx Biosciences' higher possible upside, analysts plainly believe Inhibrx Biosciences is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

Zentalis Pharmaceuticals has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.41, indicating that its share price is 241% more volatile than the broader market.

Summary

Zentalis Pharmaceuticals and Inhibrx Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Anbio Biotechnology?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Anbio Biotechnology (NASDAQ:NNNN) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Zentalis Pharmaceuticals currently has a consensus price target of $6.75, suggesting a potential upside of 55.89%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Zentalis Pharmaceuticals is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Zentalis Pharmaceuticals has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.15, meaning that its share price is 415% more volatile than the broader market.

Anbio Biotechnology's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%
Anbio Biotechnology	N/A	N/A	N/A

In the previous week, Zentalis Pharmaceuticals had 5 more articles in the media than Anbio Biotechnology. MarketBeat recorded 7 mentions for Zentalis Pharmaceuticals and 2 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.43 beat Zentalis Pharmaceuticals' score of 0.65 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Zentalis Pharmaceuticals	Positive
Anbio Biotechnology	Positive

Anbio Biotechnology has higher revenue and earnings than Zentalis Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	N/A	N/A	-$137.06M	-$1.73	N/A
Anbio Biotechnology	$8.65M	164.74	$6.40M	N/A	N/A

Summary

Anbio Biotechnology beats Zentalis Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

In the previous week, Zentalis Pharmaceuticals had 4 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 7 mentions for Zentalis Pharmaceuticals and 3 mentions for Corvus Pharmaceuticals. Corvus Pharmaceuticals' average media sentiment score of 1.50 beat Zentalis Pharmaceuticals' score of 0.65 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corvus Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zentalis Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Corvus Pharmaceuticals' return on equity of -38.92% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Zentalis Pharmaceuticals	N/A	N/A	-$137.06M	-$1.73	N/A

Corvus Pharmaceuticals has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market.

Corvus Pharmaceuticals presently has a consensus target price of $33.33, indicating a potential upside of 155.04%. Zentalis Pharmaceuticals has a consensus target price of $6.75, indicating a potential upside of 55.89%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Corvus Pharmaceuticals is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Corvus Pharmaceuticals beats Zentalis Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Ardelyx?

Ardelyx (NASDAQ:ARDX) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

58.9% of Ardelyx shares are owned by institutional investors. 5.3% of Ardelyx shares are owned by insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Ardelyx has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market.

Ardelyx currently has a consensus price target of $15.73, suggesting a potential upside of 212.67%. Zentalis Pharmaceuticals has a consensus price target of $6.75, suggesting a potential upside of 55.89%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts clearly believe Ardelyx is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Ardelyx and Ardelyx both had 7 articles in the media. Zentalis Pharmaceuticals' average media sentiment score of 0.65 beat Ardelyx's score of 0.08 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zentalis Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ardelyx has higher revenue and earnings than Zentalis Pharmaceuticals. Ardelyx is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$407.32M	3.05	-$61.60M	-$0.23	N/A
Zentalis Pharmaceuticals	N/A	N/A	-$137.06M	-$1.73	N/A

Zentalis Pharmaceuticals has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-13.58%	-38.11%	-11.85%
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%

Summary

Ardelyx beats Zentalis Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Zentalis Pharmaceuticals compare to Phibro Animal Health?

Phibro Animal Health (NASDAQ:PAHC) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Phibro Animal Health has higher revenue and earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.30B	1.06	$48.26M	$2.33	14.61
Zentalis Pharmaceuticals	N/A	N/A	-$137.06M	-$1.73	N/A

Phibro Animal Health currently has a consensus target price of $42.50, suggesting a potential upside of 24.89%. Zentalis Pharmaceuticals has a consensus target price of $6.75, suggesting a potential upside of 55.89%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Zentalis Pharmaceuticals is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Zentalis Pharmaceuticals had 3 more articles in the media than Phibro Animal Health. MarketBeat recorded 7 mentions for Zentalis Pharmaceuticals and 4 mentions for Phibro Animal Health. Phibro Animal Health's average media sentiment score of 1.59 beat Zentalis Pharmaceuticals' score of 0.65 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Zentalis Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Phibro Animal Health has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

99.3% of Phibro Animal Health shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Phibro Animal Health has a net margin of 6.35% compared to Zentalis Pharmaceuticals' net margin of 0.00%. Phibro Animal Health's return on equity of 37.14% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.35%	37.14%	8.57%
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%

Summary

Phibro Animal Health beats Zentalis Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Zentalis Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZNTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZNTL vs. The Competition

Export

Metric	Zentalis Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$316.78M	$3.67B	$6.88B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-2.50	21.11	27.00	23.71
Price / Sales	N/A	163.85	492.30	74.42
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	1.45	7.88	10.28	6.07
Net Income	-$137.06M	$23.81M	$3.60B	$331.99M
7 Day Performance	-15.26%	-3.82%	-1.29%	-0.61%
1 Month Performance	14.25%	-2.61%	-0.38%	-1.98%
1 Year Performance	194.56%	32.79%	18.32%	13.67%

Zentalis Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZNTL Zentalis Pharmaceuticals	2.4817 of 5 stars	$4.33 -2.7%	$6.75 +55.9%	+194.6%	$316.78M	N/A	N/A	160	News Coverage Analyst Forecast
INBX Inhibrx Biosciences	2.7747 of 5 stars	$92.17 -0.9%	$150.00 +62.7%	+253.5%	$1.36B	$1.30M	N/A	166	Positive News
NNNN Anbio Biotechnology	1.4117 of 5 stars	$9.97 +6.2%	N/A	N/A	$1.35B	$8.65M	N/A	27	Positive News Short Interest Decrease
CRVS Corvus Pharmaceuticals	2.943 of 5 stars	$14.71 -6.1%	$33.33 +126.6%	+175.2%	$1.32B	N/A	N/A	30	News Coverage Positive News Gap Down
ARDX Ardelyx	2.6307 of 5 stars	$5.14 -2.7%	$15.73 +206.0%	+15.4%	$1.30B	$407.32M	N/A	90	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZNTL) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zentalis Pharmaceuticals (ZNTL) Competitors

ZNTL vs. INBX, NNNN, CRVS, ARDX, and PAHC

How does Zentalis Pharmaceuticals compare to Inhibrx Biosciences?

Summary

How does Zentalis Pharmaceuticals compare to Anbio Biotechnology?

Summary

How does Zentalis Pharmaceuticals compare to Corvus Pharmaceuticals?

Summary

How does Zentalis Pharmaceuticals compare to Ardelyx?

Summary

How does Zentalis Pharmaceuticals compare to Phibro Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL vs. The Competition

Zentalis Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zentalis Pharmaceuticals (ZNTL) Competitors

ZNTL vs. INBX, NNNN, CRVS, ARDX, and PAHC

How does Zentalis Pharmaceuticals compare to Inhibrx Biosciences?

Is ZNTL or INBX more profitable?

Do insiders and institutionals have more ownership in ZNTL or INBX?

Which has better valuation and earnings, ZNTL or INBX?

Does the media prefer ZNTL or INBX?

Do analysts rate ZNTL or INBX?

Which has more volatility & risk, ZNTL or INBX?

Summary

How does Zentalis Pharmaceuticals compare to Anbio Biotechnology?

Do analysts rate ZNTL or NNNN?

Which has more risk and volatility, ZNTL or NNNN?

Is ZNTL or NNNN more profitable?

Does the media prefer ZNTL or NNNN?

Which has higher earnings & valuation, ZNTL or NNNN?

Summary

How does Zentalis Pharmaceuticals compare to Corvus Pharmaceuticals?

Does the media favor CRVS or ZNTL?

Is CRVS or ZNTL more profitable?

Which has higher valuation & earnings, CRVS or ZNTL?

Which has more risk & volatility, CRVS or ZNTL?

Do analysts recommend CRVS or ZNTL?

Do insiders and institutionals have more ownership in CRVS or ZNTL?

Summary

How does Zentalis Pharmaceuticals compare to Ardelyx?

Do institutionals and insiders hold more shares of ARDX or ZNTL?

Which has more risk and volatility, ARDX or ZNTL?

Do analysts recommend ARDX or ZNTL?

Does the media favor ARDX or ZNTL?

Which has higher earnings & valuation, ARDX or ZNTL?

Is ARDX or ZNTL more profitable?

Summary

How does Zentalis Pharmaceuticals compare to Phibro Animal Health?

Which has higher valuation and earnings, PAHC or ZNTL?

Do analysts recommend PAHC or ZNTL?

Does the media prefer PAHC or ZNTL?

Which has more volatility & risk, PAHC or ZNTL?

Do institutionals & insiders have more ownership in PAHC or ZNTL?

Is PAHC or ZNTL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZNTL vs. The Competition

Zentalis Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools